Witty On Pricing: Oncology 'No Safe Haven'

"It's time for industry and payers to start thinking about different pricing models, and it's going to require some transparency about what everything costs," said Sir Andrew Witty, speaking to Scrip on 18 April. "Lots of people will say pricing is not an issue in oncology. It's going to be an issue – it's inevitable."

Andrew Witty (GSK)

More from Immunological

More from Therapy Areas